CILcare, a contract research organization (CRO) specialized in the field of hearing, announced that they have moved their French site and are now established within a pharmaceutical park in Montpellier.The new laboratories and offices reportedly allow CILcare to “expand production capacity and better address the increasing demand for external innovation in ear diseases.”
CILcare has developed its business foundation on “unique expertise in testing, in preclinical trials, the efficacy and safety of drugs, gene and cell therapy, and implantable devices that target hearing loss, tinnitus, and otitis,” according to the company’s description. CILcare’s team is mainly composed of engineers, doctors, and experts in otology and neurosciences. The company operates worldwide from its facilities in the South of France and in Lexington, Mass, where CILcare is partnered with CBSET, a not-for-profit CRO specialized in translational sciences linked to MIT.
Although no drug has been approved for inner ear disease on the market yet, hundreds of drug candidates are being developed and some will succeed in reaching the market. CILcare’s mission is to support these development programs.
Philippe Larroze-Chicot, director of quality at CILcare, said, “The expansion of our laboratories enables us to significantly increase our production within state-of-the-art facilities. Both in the US and in France, we are now established in Big Pharma bioparks, which gives CILcare’s team all the ingredients to deliver the highest quality standards and address all of our clients’ needs.”
CILcare has “leveraged its strength in people and talent management and in process development to promote its service offering based on market needs,” according to the company’s announcement.
“Together with CBSET, we have become the one-stop-shop partner for pharma, biotech, and medtech companies targeting ear diseases. We can personally cover the whole development chain in our labs, drawing on our strong partnerships with other preclinical and clinical CROs that we specifically train on hearing and otology project specificities,” said Célia Belline, CILcare’s CEO.